Panobinostat plus bortezomib and dexamethasone for relapsed myeloma

Guy Pratt¹

Affiliations

Comment

Guy Pratt. Lancet Haematol. 2016 Nov.

. 2016 Nov;3(11):e498-e499.

doi: 10.1016/S2352-3026(16)30133-8. Epub 2016 Oct 14.

Guy Pratt¹

¹ Centre for Clinical Haematology, University Hospitals Birmingham, Birmingham B15 2TH, UK. Electronic address: guy.pratt@uhb.nhs.uk.

No abstract available

Comment on

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial.
San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Binlich F, Richardson PG. San-Miguel JF, et al. Lancet Haematol. 2016 Nov;3(11):e506-e515. doi: 10.1016/S2352-3026(16)30147-8. Epub 2016 Oct 14. Lancet Haematol. 2016. PMID: 27751707 Clinical Trial.